SCHEMBL4916718

SCHEMBL4916718

CCCc1nn(C)c2c(=O)n(CCNc3ccc(OC(C)(C)C(=O)OCC)cc3)c(CC)nc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 11/20 0.39
HDAC1 Q13547 5/20 0.39
HDAC6 Q9UBN7 5/20 0.39
PPARA Q07869 5/20 0.37
ABCB11 O95342 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
HTR2A P28223 1/20 0.37
PMP22 Q01453 1/20 0.37
PPARG P37231 2/20 0.35
POLB P06746 1/20 0.35
PDE6C P51160 1/20 0.35
HDAC2 Q92769 2/20 0.34
CNR1 P21554 1/20 0.34
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
MAPK14 Q16539 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4923154 0.95 PDE5A (0.39) PDE5AHDAC1HDAC6PPARAABCB11
SCHEMBL3847271 0.92 PDE5A (0.40) PDE5AHDAC1HDAC6PPARAABCB11
SCHEMBL4914566 0.91 PPARA (0.42) PDE5AHDAC1HDAC6PPARAPPARG
SCHEMBL4921755 0.88 PPARA (0.46) PDE5AHDAC1HDAC6PPARAABCB11
SCHEMBL3842604 0.87 PDE5A (0.39) PDE5AHDAC1HDAC6PPARAABCB11
SCHEMBL4916778 0.87 PPARA (0.41) PPARAABCB11CYP1A2CYP3A4TSHR
SCHEMBL4912662 0.87 PPARA (0.42) PDE5AHDAC1HDAC6PPARAABCB11
SCHEMBL4913969 0.86 PDE5A (0.39) PDE5AHDAC1HDAC6POLBPDE6C
SCHEMBL4916683 0.86 PPARA (0.41) PDE5AHDAC1HDAC6PPARAPPARG
SCHEMBL3911039 0.83 PPARA (0.45) PDE5AHDAC1HDAC6PPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114005-A1 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity DR. REDDY'S LABORATORIES LIMITED (IN) 2008-05-15 US disclosed
US-20080114005-A1 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity DR. REDDY'S LABORATORIES LIMITED (IN) 2008-05-15 US disclosed
US-20080114005-A1 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity DR. REDDY'S LABORATORIES LIMITED (IN) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114005-A1 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity PPARA, PPARD, PPARG PDE5A 1657/4885HDAC1 1524/4885HDAC6 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.